About: Fibrinogen-Like Protein 2 (FGL2) is a Novel Biomarker for Clinical Prediction of Human Breast Cancer

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Fibrinogen-Like Protein 2 (FGL2) is a Novel Biomarker for Clinical Prediction of Human Breast Cancer Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Fibrinogen-Like Protein 2 (FGL2) is a Novel Biomarker for Clinical Prediction of Human Breast Cancer
Creator	Wang, Wei Wang, Ting Yuan, Kai Feng, Yanyan Feng, Yuyin Huang, Guangrui Wang, Hesong Zhao, Lu Ac, Guo, Chunguang Aeg, Kai
Source	Medline; PMC
abstract	BACKGROUND: Fibrinogen-like protein 2 (FGL2) is a member of the fibrinogen-like protein family and possesses important regulatory functions in both innate and adaptive immune responses. FGL2 is overexpressed in glioma, and its expression level is negatively associated with the prognosis of glioma patients. However, the diagnostic value of FGL2 is unknown in breast carcinoma. MATERIAL/METHODS: We comprehensively analyzed the expression pattern of FGL2 in breast cancer. Several online databases – TCGA, Oncomine, GEPIA, Kaplan-Meier plotter, and PrognoScan – were used in this study. RESULTS: Based on the TCGA dataset and Oncomine database, we found that the expression level of FGL2 was remarkably lower in breast cancer compared with adjacent normal tissues. Clinical data showed that the expression level of FGL2 was significantly associated with radiation therapy, PR status, and tumor stage. Bioinformatics analysis of the GEPIA, Kaplan-Meier plotter, and PrognoScan databases showed that lower FGL2 expression levels were associated with a worse prognosis in breast cancer patients. Furthermore, the expression level of FGL2 was positively correlated with the immune cell infiltrations in breast cancer, especially those cells with high antitumor activities. GO, KEGG, and GSEA analyses also validated that FGL2 was closely related to genes involved in the immune response, signal transduction, and T cell receptor signaling pathway in breast cancer. CONCLUSIONS: The results demonstrated that high expression of FGL2 is a useful marker for breast cancer treatment and appears to be correlated with enhanced antitumor activities in breast cancer patients.
has issue date	2020-07-27(xsd:dateTime)
bibo:doi	10.12659/msm.923531
bibo:pmid	32716910
has license	cc-by-nc-nd
sha1sum (hex)	b2ee4ca72134b552db359e6bea533f9b2a5fccff
schema:url	https://doi.org/10.12659/msm.923531
resource representing a document's title	Fibrinogen-Like Protein 2 (FGL2) is a Novel Biomarker for Clinical Prediction of Human Breast Cancer
has PubMed Central identifier	PMC7409386
has PubMed identifier	32716910
schema:publication	Med Sci Monit
resource representing a document's body	covid:b2ee4ca72134b552db359e6bea533f9b2a5fccff#body_text
is schema:about of	named entity 'prognosis' named entity 'Breast Cancer' named entity 'Prediction' named entity 'ASSOCIATED WITH' named entity 'glioma' named entity 'functions' named entity 'Protein' named entity 'protein family' named entity 'glioma' named entity 'Fibrinogen-like protein 2' named entity 'adaptive immune responses' named entity 'breast cancer' named entity 'microarray' named entity 'expression levels' named entity 'breast cancer' named entity 'positively correlated' named entity 'breast cancer' named entity 'signaling pathway' named entity 'tumor' named entity 'class II gene' named entity 'tumor' named entity 'TCGA' named entity 'FN1' named entity 'negatively correlated' named entity 'KEGG' named entity 'tumor' named entity 'signal transduction' named entity 'HLA' named entity 'MYC' named entity 'receptor' named entity 'cell receptor' named entity 'multimeric' named entity 'oxidative phosphorylation' named entity 'FN1' named entity 'breast cancer' named entity 'biomarker' named entity 'pleiotropic effects' named entity 'upregulated' named entity 'cytokine receptor' named entity 'positively correlated' named entity 'mRNA' named entity 'transcription' named entity 'tumor' named entity 'KEGG' named entity 'IFN-a' named entity 'immune cell' named entity 'angiogenesis' named entity 'fibrinogen' named entity 'macrophages' named entity 'breast cancer' named entity 'breast cancer' named entity 'receptor' named entity 'breast cancer' named entity 'breast invasive carcinoma' named entity 'CD8 +' named entity 'tumor' named entity 'CD8 +' named entity 'metabolism' named entity 'Th1' named entity 'upregulation' named entity 'therapeutic targets' named entity 'CD4' named entity 'morbidity rate' named entity 'TCGA' named entity 'KEGG' named entity 'antitumor' named entity 'natural killer cells' named entity 'CD4' named entity 'immune response' named entity 'breast cancer' named entity 'breast cancer'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software